|
US5206344A
(en)
*
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4766106A
(en)
*
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US5525338A
(en)
*
|
1992-08-21 |
1996-06-11 |
Immunomedics, Inc. |
Detection and therapy of lesions with biotin/avidin conjugates
|
|
US4810638A
(en)
*
|
1986-07-24 |
1989-03-07 |
Miles Inc. |
Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
|
|
DE3889853D1
(de)
*
|
1987-11-05 |
1994-07-07 |
Hybritech Inc |
Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
|
|
US4847325A
(en)
*
|
1988-01-20 |
1989-07-11 |
Cetus Corporation |
Conjugation of polymer to colony stimulating factor-1
|
|
FR2626373B1
(fr)
*
|
1988-01-22 |
1993-10-15 |
Stabiligen |
Procede de preparation d'un traceur stable et traceur obtenu
|
|
US5541297A
(en)
*
|
1988-04-01 |
1996-07-30 |
Immunomedics, Inc. |
Therapeutic conjugates of toxins and drugs
|
|
US5306500A
(en)
*
|
1988-11-21 |
1994-04-26 |
Collagen Corporation |
Method of augmenting tissue with collagen-polymer conjugates
|
|
US5162430A
(en)
*
|
1988-11-21 |
1992-11-10 |
Collagen Corporation |
Collagen-polymer conjugates
|
|
US5565519A
(en)
*
|
1988-11-21 |
1996-10-15 |
Collagen Corporation |
Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
|
|
US5510418A
(en)
*
|
1988-11-21 |
1996-04-23 |
Collagen Corporation |
Glycosaminoglycan-synthetic polymer conjugates
|
|
US4902502A
(en)
*
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US5166322A
(en)
*
|
1989-04-21 |
1992-11-24 |
Genetics Institute |
Cysteine added variants of interleukin-3 and chemical modifications thereof
|
|
GB8909711D0
(en)
*
|
1989-04-27 |
1989-06-14 |
Secr Defence |
Optical beam steering device
|
|
US5527528A
(en)
*
|
1989-10-20 |
1996-06-18 |
Sequus Pharmaceuticals, Inc. |
Solid-tumor treatment method
|
|
US5620689A
(en)
*
|
1989-10-20 |
1997-04-15 |
Sequus Pharmaceuuticals, Inc. |
Liposomes for treatment of B-cell and T-cell disorders
|
|
DE4004296A1
(de)
*
|
1990-02-13 |
1991-08-14 |
Hoechst Ag |
Verbesserte markierte haptene, verfahren zu deren herstellung sowie verwendung dieser markierten haptene in immunoassays
|
|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
|
SE468238B
(sv)
*
|
1990-02-28 |
1992-11-30 |
Sten Ohlson |
Laekemedel med svag affinitet
|
|
US5951972A
(en)
*
|
1990-05-04 |
1999-09-14 |
American Cyanamid Company |
Stabilization of somatotropins and other proteins by modification of cysteine residues
|
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
|
US5885570A
(en)
*
|
1991-01-23 |
1999-03-23 |
The General Hospital Corporation |
Induction of tolerance with modified immunogens
|
|
US5595732A
(en)
*
|
1991-03-25 |
1997-01-21 |
Hoffmann-La Roche Inc. |
Polyethylene-protein conjugates
|
|
US5336782A
(en)
*
|
1991-04-24 |
1994-08-09 |
Kuraray Co., Ltd. |
Long chain carboxylic acid imide ester
|
|
US5169627A
(en)
*
|
1991-10-28 |
1992-12-08 |
Mount Sinai School Of Medicine Of The City University Of New York |
Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
|
|
US6217869B1
(en)
|
1992-06-09 |
2001-04-17 |
Neorx Corporation |
Pretargeting methods and compounds
|
|
US5846741A
(en)
*
|
1992-08-21 |
1998-12-08 |
Immunomedics, Inc. |
Boron neutron capture therapy using pre-targeting methods
|
|
US5382657A
(en)
*
|
1992-08-26 |
1995-01-17 |
Hoffmann-La Roche Inc. |
Peg-interferon conjugates
|
|
CA2101361A1
(en)
*
|
1992-08-27 |
1994-02-28 |
Robert A. Snow |
Low diol polyalkylene oxide biologically active proteinaceous substances
|
|
GB9225448D0
(en)
*
|
1992-12-04 |
1993-01-27 |
Erba Carlo Spa |
Improved synthesis of polymer bioactive conjugates
|
|
KR100361933B1
(ko)
*
|
1993-09-08 |
2003-02-14 |
라 졸라 파마슈티칼 컴파니 |
화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
|
|
WO1995012413A1
(en)
*
|
1993-11-03 |
1995-05-11 |
O'brien, Caroline, Jane |
Cell control and suppression
|
|
US6015897A
(en)
*
|
1993-12-07 |
2000-01-18 |
Neorx Corporation |
Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota
|
|
IT1268955B1
(it)
*
|
1994-03-11 |
1997-03-18 |
Fidia Advanced Biopolymers Srl |
Esteri attivi di polisaccaridi carbossilici
|
|
US5670132A
(en)
*
|
1994-09-20 |
1997-09-23 |
Immunomedics, Inc. |
Modified radioantibody fragments for reduced renal uptake
|
|
US6908903B1
(en)
|
1994-12-07 |
2005-06-21 |
Aletheon Pharmaceuticals, Inc. |
Cluster clearing agents
|
|
US6172045B1
(en)
|
1994-12-07 |
2001-01-09 |
Neorx Corporation |
Cluster clearing agents
|
|
US5695760A
(en)
*
|
1995-04-24 |
1997-12-09 |
Boehringer Inglehiem Pharmaceuticals, Inc. |
Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
|
|
CA2220339C
(en)
|
1995-05-10 |
2009-10-13 |
Kyowa Hakko Kogyo Co., Ltd. |
Toxin conjugates having a spacer comprising polyalkylene glycol and peptide
|
|
US6458889B1
(en)
|
1995-12-18 |
2002-10-01 |
Cohesion Technologies, Inc. |
Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
|
|
US7883693B2
(en)
*
|
1995-12-18 |
2011-02-08 |
Angiodevice International Gmbh |
Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
|
|
US6833408B2
(en)
*
|
1995-12-18 |
2004-12-21 |
Cohesion Technologies, Inc. |
Methods for tissue repair using adhesive materials
|
|
WO1997022371A1
(en)
|
1995-12-18 |
1997-06-26 |
Collagen Corporation |
Crosslinked polymer compositions and methods for their use
|
|
JP4469025B2
(ja)
*
|
1996-02-01 |
2010-05-26 |
オルバニー メディカル カレッジ |
細胞の抗原による免疫調整
|
|
US8007784B1
(en)
|
1996-06-27 |
2011-08-30 |
Albany Medical College |
Antigenic modulation of cells
|
|
EP0973384A4
(en)
|
1997-02-13 |
2004-10-13 |
Sky High Llc |
ORGAN PRESERVATION SOLUTION
|
|
CA2281794A1
(en)
|
1997-02-21 |
1998-08-27 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies
|
|
US7122636B1
(en)
*
|
1997-02-21 |
2006-10-17 |
Genentech, Inc. |
Antibody fragment-polymer conjugates and uses of same
|
|
DE19748489A1
(de)
*
|
1997-11-03 |
1999-05-06 |
Roche Diagnostics Gmbh |
Polyethylenglykol-derivatisierte Biomoleküle und deren Verwendung in heterogenen Nachweisverfahren
|
|
US6468532B1
(en)
|
1998-01-22 |
2002-10-22 |
Genentech, Inc. |
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
|
|
US7005504B2
(en)
*
|
1998-01-22 |
2006-02-28 |
Genentech, Inc. |
Antibody fragment-peg conjugates
|
|
US6458355B1
(en)
|
1998-01-22 |
2002-10-01 |
Genentech, Inc. |
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
|
|
BR9909130A
(pt)
|
1998-03-26 |
2000-12-19 |
Procter & Gamble |
Variantes de protease de serina tendo substituições de amino-ácido
|
|
US6495136B1
(en)
|
1998-03-26 |
2002-12-17 |
The Procter & Gamble Company |
Proteases having modified amino acid sequences conjugated to addition moieties
|
|
US6908757B1
(en)
|
1998-03-26 |
2005-06-21 |
The Procter & Gamble Company |
Serine protease variants having amino acid deletions and substitutions
|
|
ATE298251T1
(de)
|
1998-08-06 |
2005-07-15 |
Mountain View Pharmaceuticals |
Peg-uricase konjugate und verwendung davon
|
|
DE69914611T2
(de)
*
|
1998-08-28 |
2004-12-23 |
Gryphon Therapeutics, Inc., South San Francisco |
Verfahren zur herstellung von polyamidketten von genauer länge und deren konjugate mit proteinen
|
|
ATE263778T1
(de)
*
|
1998-10-30 |
2004-04-15 |
Novozymes As |
Niedrigallergene proteinvarianten
|
|
US6458953B1
(en)
*
|
1998-12-09 |
2002-10-01 |
La Jolla Pharmaceutical Company |
Valency platform molecules comprising carbamate linkages
|
|
JP2003505067A
(ja)
|
1999-07-22 |
2003-02-12 |
ザ、プロクター、エンド、ギャンブル、カンパニー |
特定のエピトープ領域にアミノ酸欠失及び置換を有するサブチリシンプロテアーゼの変異体
|
|
US6946128B1
(en)
|
1999-07-22 |
2005-09-20 |
The Procter & Gamble Company |
Protease conjugates having sterically protected epitope regions
|
|
MXPA02000842A
(es)
|
1999-07-22 |
2002-07-30 |
Procter & Gamble |
Conjugados de proteasa que tienen sitios de corte protegidos estericamente.
|
|
WO2001007578A2
(en)
|
1999-07-22 |
2001-02-01 |
The Procter & Gamble Company |
Subtilisin protease variants having amino acid substitutions in defined epitope regions
|
|
EP1221482B1
(en)
*
|
1999-09-27 |
2005-12-28 |
Chugai Seiyaku Kabushiki Kaisha |
Hemopoietin receptor protein, nr12
|
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
|
CA2389979C
(en)
|
1999-11-24 |
2011-08-16 |
Schering Corporation |
Methods of inhibiting metastasis
|
|
ES2317898T3
(es)
|
2000-04-18 |
2009-05-01 |
Schering Corporation |
Usos medicinales de agonistas y antogonistas de il-174.
|
|
IL153218A0
(en)
|
2000-06-02 |
2003-07-06 |
Univ Texas |
Ethylenedicysteine (ec) -drug conjugates
|
|
CA2414076A1
(en)
|
2000-06-08 |
2001-12-13 |
La Jolla Pharmaceutical Company |
Multivalent platform molecules comprising high molecular weight polyethylene oxide
|
|
JP4334866B2
(ja)
|
2000-10-09 |
2009-09-30 |
アイシス イノヴェイション リミテッド |
治療用抗体
|
|
CA2444483A1
(en)
*
|
2001-04-26 |
2002-11-07 |
Board Of Regents, The University Of Texas System |
Diagnostic imaging compositions, their methods of synthesis and use
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
|
MXPA04007426A
(es)
|
2002-02-01 |
2004-10-11 |
Schering Corp |
Usos de citosina de mamifero; reactivos relacionados.
|
|
GB0202906D0
(en)
|
2002-02-07 |
2002-03-27 |
Univ London |
Prevention of myocardial damage
|
|
MY147019A
(en)
*
|
2002-03-13 |
2012-10-15 |
Biogen Idec Inc |
Anti-alpha v beta 6 antibodies
|
|
EP1494706A4
(en)
*
|
2002-03-26 |
2006-10-25 |
Biosynexus Inc |
ANTIMICROBIAL POLYMER CONJUGATES
|
|
AU2003297261B2
(en)
*
|
2002-11-07 |
2008-10-23 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
|
AU2003303384A1
(en)
|
2002-12-23 |
2004-07-22 |
Schering Corporation |
Uses of mammalian cytokine; related reagents
|
|
GEP20084486B
(en)
*
|
2002-12-26 |
2008-09-25 |
Mountain View Pharmaceuticals |
Polymer conjugates of interferon-beta with enhanced biological potency
|
|
RS20050501A
(sr)
*
|
2002-12-26 |
2007-08-03 |
Mountain View Pharmaceuticals Inc., |
Polimerni konjugati citokina,hemokina,faktora rasta, polipeptidnih hormona i njihovih antagonista sa očuvanom aktivnošću vezivanja receptora
|
|
WO2004060346A2
(en)
|
2002-12-30 |
2004-07-22 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
|
AU2003303513A1
(en)
*
|
2002-12-30 |
2004-07-29 |
Angiotech International Ag |
Tissue reactive compounds and compositions and uses thereof
|
|
WO2004097019A1
(ja)
*
|
2003-04-30 |
2004-11-11 |
Japan Science And Technology Agency |
ヒト抗ヒトインターロイキン-18抗体およびその断片、並びにそれらの利用方法
|
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
|
NZ550964A
(en)
|
2004-04-28 |
2011-05-27 |
Angiodevice Internat Gmbh |
Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
|
|
US20090035784A1
(en)
*
|
2004-07-30 |
2009-02-05 |
Mount Sinai School Of Medicine Of New York University |
Npc1l1 and npc1l1 inhibitors and methods of use thereof
|
|
WO2006034128A2
(en)
|
2004-09-17 |
2006-03-30 |
Angiotech Biomaterials Corporation |
Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
|
|
KR100754667B1
(ko)
|
2005-04-08 |
2007-09-03 |
한미약품 주식회사 |
비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물
|
|
KR20080009111A
(ko)
|
2005-04-11 |
2008-01-24 |
새비언트 파마수티컬즈 인크. |
유레이트 옥시다아제의 변이형 및 이의 용도
|
|
US8148123B2
(en)
|
2005-04-11 |
2012-04-03 |
Savient Pharmaceuticals, Inc. |
Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
|
|
MX2007012548A
(es)
|
2005-04-11 |
2008-03-11 |
Savient Pharmaceuticals Inc |
Formas variantes de urato oxidasa y uso de las mismas.
|
|
US20060246523A1
(en)
|
2005-04-28 |
2006-11-02 |
Christopher Bieniarz |
Antibody conjugates
|
|
EP1893241A2
(en)
*
|
2005-04-28 |
2008-03-05 |
Ventana Medical Systems, Inc. |
Fluorescent nanoparticles conjugated to antibodies via a peg linker
|
|
CN102875681A
(zh)
|
2005-07-08 |
2013-01-16 |
拜奥根Idec马萨诸塞公司 |
抗-αvβ6抗体及其用途
|
|
WO2007058129A1
(ja)
*
|
2005-11-18 |
2007-05-24 |
Nitto Boseki Co., Ltd. |
抗原の測定法およびそれに用いるキット
|
|
CN104090095B
(zh)
*
|
2005-11-23 |
2016-06-01 |
文塔纳医疗系统公司 |
分子缀合物
|
|
CU23556A1
(es)
|
2005-11-30 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico
|
|
EP2004231A4
(en)
|
2006-04-07 |
2013-07-10 |
Nektar Therapeutics |
CONJUGATES OF ANTI-TNF-ALPHA ANTIBODY
|
|
KR101288027B1
(ko)
|
2006-04-12 |
2013-07-22 |
새비언트 파마수티컬즈 인크. |
양이온 계면활성제를 이용한 단백질 정제 방법
|
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
|
WO2010078376A2
(en)
*
|
2008-12-30 |
2010-07-08 |
Ventana Medical Systems, Inc. |
Fc-specific polymer-conjugated antibodies and their diagnostic use
|
|
EP3543256A1
(en)
|
2009-01-12 |
2019-09-25 |
Cytomx Therapeutics Inc. |
Modified antibody compositions, methods of making and using thereof
|
|
JP2012531596A
(ja)
|
2009-06-25 |
2012-12-10 |
サヴィエント・ファーマシューティカルズ・インコーポレイテッド |
Peg化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
|
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
|
WO2012012352A2
(en)
*
|
2010-07-19 |
2012-01-26 |
Amidebio, Llc |
Modified peptides and proteins
|
|
EP2630077B1
(en)
*
|
2010-10-18 |
2018-09-19 |
University of Washington through its Center for Commercialization |
Chromophoric polymer dots
|
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
|
KR20150133576A
(ko)
*
|
2014-05-20 |
2015-11-30 |
삼성전자주식회사 |
화학적 개질된 표적화 단백질 및 그의 이용
|
|
EP3253403B1
(en)
|
2015-02-06 |
2021-09-01 |
The Regents of The University of California |
Methods and compositions for improved cognition
|
|
CN116637177A
(zh)
|
2016-11-11 |
2023-08-25 |
好利恩治疗美国公司 |
泼尼松和尿酸酶分子的组合疗法及其用途
|
|
WO2019036433A2
(en)
|
2017-08-16 |
2019-02-21 |
Bristol-Myers Squibb Company |
ANTIBODIES IN THE FORM OF PRODRUGS, PRODRUGS BASED THEREON, THEIR METHODS OF USE AND PREPARATION
|
|
WO2020160325A1
(en)
|
2019-01-30 |
2020-08-06 |
Horizon Pharma Rheumatology Llc |
Reducing immunogenicity to pegloticase
|
|
EP3920887B1
(en)
|
2019-02-04 |
2024-08-14 |
The Regents of the University of California |
A phosphatidylinositol-glycan-specific phospholipase d1 (gpld1) polypeptide for use in a method of treating or preventing age-related cognitive dysfunction
|
|
US20220251206A1
(en)
|
2019-06-11 |
2022-08-11 |
Bristol-Myers Squibb Company |
Anti-ctla4 antibody prodruggable (probody) at a cdr position
|
|
CN110672836B
(zh)
*
|
2019-09-30 |
2023-03-21 |
香港大德昌龙生物科技有限公司 |
磁珠包被物及其制备方法和应用、检测试剂盒
|
|
WO2021163272A2
(en)
|
2020-02-12 |
2021-08-19 |
The Regents Of The University Of California |
Platelet factors and cognitive improvement
|
|
TW202434279A
(zh)
|
2022-10-28 |
2024-09-01 |
美商聯合生物技術公司 |
用於改善認知之方法
|
|
US12269875B2
(en)
|
2023-08-03 |
2025-04-08 |
Jeff R. Peterson |
Gout flare prevention methods using IL-1BETA blockers
|